Drug Profile


Alternative Names: MSC-apceth-101

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apceth
  • Class Antineoplastics; Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastrointestinal cancer

Most Recent Events

  • 11 Sep 2017 Agenmestencel-T is still in phase II development for Gastrointestinal cancer (Late-stage disease, Metastatic disease) in Germany (Apceth pipeline, September 2017)
  • 23 Mar 2017 Apceth terminates a phase I/II trial in Gastrointestinal cancer (Late-stage disease, Metastatic disease) in Germany as patients did not meet eligibility criteria (NCT02008539)
  • 26 Mar 2015 Phase-II clinical trials in Gastrointestinal cancer (Late-stage disease, Metastatic disease) in Germany (IV) (9176594; NCT02008539)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top